China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 7,347,822 shares, a growth of 115.5% from the January 15th total of 3,408,880 shares. Currently, 794.4% of the company’s shares are sold short. Based on an average daily trading volume, of 35,892,593 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 35,892,593 shares, the days-to-cover ratio is currently 0.2 days. Currently, 794.4% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A hedge fund recently bought a new stake in China SXT Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 48,759 shares of the company’s stock, valued at approximately $78,000. 5.02% of the stock is currently owned by institutional investors.

China SXT Pharmaceuticals Price Performance

NASDAQ:SXTC remained flat at $2.49 on Thursday. The company’s stock had a trading volume of 21,566 shares, compared to its average volume of 558,768. The business has a fifty day moving average of $124.09 and a two-hundred day moving average of $192.15. China SXT Pharmaceuticals has a 12 month low of $2.34 and a 12 month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.